findmyKOL
Clinical trialNCT02869633CompletedPhase 2Interventional

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

SponsorVanderbilt-Ingram Cancer CenterEnrollment23Blastoid Variant Mantle Cell LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Hodgkin LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic Leukemia+3 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, United States

  • Stanford Cancer Institute

    Palo Alto, California, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, United States

  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ibrutinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2016
Primary completion
18 Nov 2021
Completion
31 Oct 2023
Last update posted
23 Oct 2023
Registered enrollment
23
Registry id
NCT02869633
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.